Fusion Pharmaceuticals Inc. announced the company has entered into a strategic research collaboration with Pepscan Therapeutics B.V. (Pepscan) to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. Under the agreement, Fusion has global rights to develop and commercialize any peptides discovered under the
collaboration.